Literature DB >> 30655216

Synthesis and biological evaluation of 3-amino-, 3-alkoxy- and 3-aryloxy-6-(hetero)arylpyridazines as potent antitumor agents.

Stéphane Sengmany1, Mathilde Sitter1, Eric Léonel2, Erwan Le Gall1, Gervaise Loirand3, Thierry Martens1, Didier Dubreuil4, Florian Dilasser3, Morgane Rousselle3, Vincent Sauzeau3, Jacques Lebreton4, Muriel Pipelier4, Rémy Le Guével5.   

Abstract

Various 3-amino-, 3-aryloxy- and alkoxy-6-arylpyridazines have been synthesized by an electrochemical reductive cross-coupling between 3-amino-, 3-aryloxy- or 3-alkoxy-6-chloropyridazines and aryl or heteroaryl halides. In vitro antiproliferative activity of these products was evaluated against a representative panel of cancer cell lines (HuH7, CaCo-2, MDA-MB-231, HCT116, PC3, NCI-H727, HaCaT) and oncogenicity prevention of the more efficient derivatives was highlighted on human breast cancer cell line MDA-MB 468-Luc prior establishing their interaction with p44/42 and Akt-dependent signaling pathways.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Arylpyridazines; Biological evaluation; Cytotoxic activity; Electrosynthesis; Nickel catalysis

Mesh:

Substances:

Year:  2018        PMID: 30655216     DOI: 10.1016/j.bmcl.2018.12.050

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights.

Authors:  Ahmed Sabt; Wagdy M Eldehna; Tarfah Al-Warhi; Ohoud J Alotaibi; Mahmoud M Elaasser; Howayda Suliman; Hatem A Abdel-Aziz
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

Review 2.  Recent Advancements in the Development of Anti-Breast Cancer Synthetic Small Molecules.

Authors:  Eslam B Elkaeed; Hayam A Abd El Salam; Ahmed Sabt; Ghada H Al-Ansary; Wagdy M Eldehna
Journal:  Molecules       Date:  2021-12-15       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.